| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.PAS.0000209827.39477.4F |
| P698 | PubMed publication ID | 16931959 |
| P2093 | author name string | Anthony J Gill | |
| Henning Dralle | |||
| Oliver Gimm | |||
| Deborah J Marsh | |||
| Viive M Howell | |||
| Adele Clarkson | |||
| Juliane Keil | |||
| P433 | issue | 9 | |
| P304 | page(s) | 1140-1149 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | The American Journal of Surgical Pathology | Q7713508 |
| P1476 | title | Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias | |
| P478 | volume | 30 |
| Q95409860 | Q95409860 |
| Q36680526 | 5-Hydroxymethylcytosine discriminates between parathyroid adenoma and carcinoma |
| Q52879694 | A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome. |
| Q87622439 | A case of parathyroid carcinoma accompanied by a brown tumor |
| Q52606764 | Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. |
| Q58697890 | Autoinfarction of Giant Parathyroid Adenoma after Preoperative Withdrawal of Anticoagulants |
| Q59417382 | Biomarkers of Parathyroid Carcinoma |
| Q37358248 | CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. |
| Q57748219 | CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort |
| Q53350124 | Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. |
| Q37341805 | Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma |
| Q92379171 | Current concepts in parathyroid carcinoma: a single Centre experience |
| Q44557302 | Defining a molecular phenotype for benign and malignant parathyroid tumors |
| Q53749111 | Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. |
| Q36037109 | Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. |
| Q36444814 | Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas |
| Q57779061 | Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma |
| Q35894421 | Early Onset Primary Hyperparathyroidism Associated with a Novel Germline Mutation in CDKN1B. |
| Q37378253 | Evaluation of malignant parathyroid tumours in two European cohorts of patients with sporadic primary hyperparathyroidism |
| Q50656399 | Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. |
| Q41766499 | Expression of parafibromin in major renal cell tumors |
| Q27025359 | Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors |
| Q34264055 | Genetic characterization of large parathyroid adenomas |
| Q34431091 | Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors. |
| Q37353629 | Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment |
| Q34630850 | Hyperparathyroidism-jaw tumor syndrome: Results of operative management |
| Q84073002 | Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred |
| Q58497279 | Identification of De Novo Germline Mutations in the HRPT2 Gene in Two Apparently Sporadic Cases with Challenging Parathyroid Tumor Diagnoses |
| Q40758523 | Immunohistochemical Expression of E-Cadherin in Atypical Parathyroid Adenoma. |
| Q52601593 | Immunohistochemistry in Diagnostic Parathyroid Pathology. |
| Q33803018 | Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome |
| Q54254767 | Molecular Characteristics of Large Parathyroid Adenomas. |
| Q35910367 | Molecular alterations in sporadic primary hyperparathyroidism |
| Q37448279 | Molecular genetics of parathyroid disease. |
| Q45907440 | Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. |
| Q38193373 | Molecular profiling in primary hyperparathyroidism. |
| Q39412594 | Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood |
| Q37274291 | Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery |
| Q34429448 | Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas |
| Q92842127 | OVARIAN GRANULOSA CELL TUMOR IN A PATIENT WITH A PATHOGENIC VARIANT IN THE CDC73 GENE (HYPERPARATHYROIDISM-JAW TUMOR SYNDROME) |
| Q41775003 | Parafibromin Staining Characteristics in Urothelial Carcinomas and Relationship with Prognostic Parameters |
| Q50692553 | Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. |
| Q41296038 | Parafibromin as a diagnostic instrument for parathyroid carcinoma-lone ranger or part of the posse? |
| Q84475566 | Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma |
| Q92688380 | Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center |
| Q87363127 | Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer |
| Q49927230 | Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. |
| Q51746485 | Parathyroid Carcinoma Encountered After Minimally Invasive Focused Parathyroidectomy may not Require Further Radical Surgery |
| Q42935904 | Parathyroid adenoma |
| Q26796612 | Parathyroid cancer |
| Q34686824 | Parathyroid cancer |
| Q60482584 | Parathyroid carcinoma |
| Q34792877 | Parathyroid carcinoma arising from four-gland hyperplasia. |
| Q37716743 | Parathyroid carcinoma: a review |
| Q35583695 | Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics |
| Q37860135 | Parathyroid tumors and related disorders |
| Q38777548 | Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. |
| Q37133266 | Significance of Parafibromin Expression in Laryngeal Squamous Cell Carcinomas |
| Q33358543 | The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3. |
| Q45879500 | The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy |
| Q38176824 | Understanding the genetic basis of parathyroid carcinoma |
| Q38784218 | Update on parathyroid carcinoma |
| Q38013656 | Water-clear parathyroid adenoma: report of two cases and literature review |
| Q83033935 | [Indication and performance of endocrine surgery. The significance of molecular genetic examination] |
| Q53535026 | [Pathology of parathyroid glands: Practical aspects for routine pathological investigations]. |
Search more.